Research programme: VEGF cardiovascular gene therapy - Collateral Therapeutics

Drug Profile

Research programme: VEGF cardiovascular gene therapy - Collateral Therapeutics

Alternative Names: CORGENIC; GENECOR; GENEVX; MYOCOR

Latest Information Update: 02 Jul 2007

Price : $50

At a glance

  • Originator Bayer Schering Pharma; Cardium Therapeutics
  • Developer Cardium Therapeutics
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inducing agents; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 17 Jul 2002 Schering AG has acquired Collateral Therapeutics
  • 17 Jan 2000 Preclinical development for Cardiovascular disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top